Toyobo Co stock analysis
Want to see JP:3101 full AI Analyst Report?
Toyobo Co (3101) Stock Price & Analysis
3101 Stock Chart & Stats
- Day’s Range
- JPY 1,367.00 - JPY 1,416.00
- 52-Week Range
- JPY 1,123.00 - JPY 1,945.00
- Previous Close
- JPY 1,488.00
- Volume
- N/A
- Average Volume (3M)
- 460.22K
- Market Cap
- JPY 125.08B
- Enterprise Value
- JPY 404.24B
- Total Cash (Recent Filing)
- JPY 30.79B
- Total Debt (Recent Filing)
- JPY 265.12B
- Price to Earnings (P/E)
- 14.9
- Beta
- 1.26
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 2.84%
Bulls Say, Bears Say
Bulls Say
2026 Operating Rebound
Revenue reached approximately ¥422B in 2025 and 2026, while 2026 brought a strong profit rebound. This scale and renewed earnings momentum indicate improved operating traction, although durability still depends on maintaining product mix and cost discipline.
Improved Cash Generation
Operating cash flow rose substantially and free cash flow turned positive after several weak years. Better internal cash generation can support investment, debt service, and strategic flexibility, strengthening resilience if the improvement persists through future operating cycles.
Diversified Materials Portfolio
Toyobo serves multiple end markets through fibers, films, industrial plastics, functional materials, and bio-related products. This breadth can diversify revenue exposure and create opportunities to shift toward higher-value specialty offerings across industrial and healthcare customers.
Bears Say
Profitability Volatility
Profitability has been inconsistent, including a loss in 2023, thin profits in 2024–2025, and a strong rebound in 2026. Such swings weaken earnings visibility and suggest results remain sensitive to costs, pricing, product mix, and industry cycles.
Historically Weak Free Cash Flow
Free cash flow was negative in every year from 2022 through 2025 before turning positive in 2026. This extended shortfall indicates investment or working-capital demands repeatedly outpaced internally generated cash, potentially limiting funding flexibility.
Elevated Leverage
Debt-to-equity remained approximately 1.0–1.37 from 2022–2025, with total debt of roughly ¥191B–¥268B. Although equity reached about ¥213B in 2026, leverage can constrain financial flexibility and amplify pressure during weaker earnings periods.
3101 FAQ
What was Toyobo Co’s price range in the past 12 months?
What is Toyobo Co’s market cap?
When is Toyobo Co’s upcoming earnings report date?
How were Toyobo Co’s earnings last quarter?
Is Toyobo Co overvalued?
Does Toyobo Co pay dividends?
What is Toyobo Co’s EPS estimate?
How many shares outstanding does Toyobo Co have?
What happened to Toyobo Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Toyobo Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Toyobo Co
Established in 1882 and headquartered in Osaka, Japan, Toyobo Co., Ltd. is a global enterprise delivering a diverse range of products. The company specializes in the manufacturing of films and advanced polymers, industrial components, healthcare solutions, and various textile goods. Its films and functional polymers division produces industrial PET films for applications such as liquid crystal displays and optics, in addition to synthetic papers. It also supplies a variety of packaging films, including PET, polyolefin, and nylon options for food products, along with heat-shrink PET films. The company's portfolio of functional polymers features engineering plastics, industrial adhesives, specialized coatings, photosensitive printing plates, acrylate polymers, and electronic materials. This segment further encompasses rubber and coat processing, as well as pharmaceutical intermediates. Within its industrial materials segment, Toyobo develops functional fibers for airbag construction, polyethylene fibers, and PBO fibers. It also creates functional filters for automotive and indoor environments, materials for anti-pollution solvent adsorption, and fiber components utilized in vehicle parts. In the healthcare sector, the company provides a comprehensive selection of bio-products, which includes enzymes for diagnostic purposes, diagnostic systems, and research reagents. Its contributions also extend to artificial kidney hollow fibers, anti-clotting substances, and seawater desalination modules. For textiles, Toyobo supplies functional fabrics suitable for sports clothing, undergarments, and uniforms, alongside synthetic filaments. The company markets apparel under its Munsingwear brand, acrylic fibers under Exlan, and acrylate fibers under the eks brand, while also engaging in general textile product commerce. Beyond these offerings, Toyobo serves as a contract manufacturer for injectable pharmaceuticals.
- Sector
- Basicmaterials
- Industry
- Chemicals - Specialty
- CEO
- Ikuo Takeuchi
- Employees
- 9,398
- Website
- www.toyobo.co.jp
- Address
- Osaka Umeda Twin Towers South, Kita, OS, 530-0001, JP
Toyobo Co (3101) Earnings & Revenues
3101 Company Deck
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |








